2024年10月7日 · Palbociclib is used to treat adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. It should always be used in combination with another medicine either: fulvestrant in patients with disease progression following endocrine therapy. The most common side effects of palbociclib are:

Palbociclib is a medication that stops cancer cells from growing. It treats breast cancer. This type of cancer occurs when cells in your breast grow and divide in an uncontrolled way, creating a mass of tissue called a tumor.

Palbociclib is a targeted or biological therapy drug. When used to treat breast cancer, palbociclib is taken alongside hormone (endocrine) therapy. Palbociclib is the drug’s non-branded name. Its brand name is Ibrance. It belongs to a group of drugs …

Palbociclib works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow. Blocking these proteins may slow or stop the growth of cancer cells. Palbociclib is a type of targeted therapy drug called a kinase inhibitor.

2024年7月10日 · It treats breast cancer that is advanced or has spread to other parts of the body (metastatic) and is hormone receptor (HR)-positive and human epidermal growth factor receptor 2...

Palbociclib is used to treat hormone receptor (HR)-positive, HER-2 negative advanced or metastatic (cancer that has spread) breast cancer. This medicine is used in combination with an aromatase inhibitor (eg, letrozole) as first hormonal based treatment or with fulvestrant in patients with disease progression following hormonal treatment.

Palbociclib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.

Palbociclib is a type of cancer growth blocker that targets the proteins cyclin dependant kinase 4 and 6 (CDK4 and CDK6) on cancer cells. CDK 4 and CDK 6 are proteins that stimulate cancer cells to grow and divide.

2025年4月4日 · Dr. Finn: Palbociclib is an oral drug that inhibits two proteins, CDK4 and CDK6, which regulate cell division. In cancer, cell division is uncontrolled. Palbociclib helps slow this process, and when combined with endocrine therapy, the two work together to halt tumor growth. How did the team first identify palbociclib as a promising drug candidate?

Medscape - Breast cancer dosing for Ibrance (palbociclib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.